Recently, one study demonstrated both circulating tumor cells exhibiting an active EMT status (vimentin+ and EGFR+) and tumoral expression of AXL mRNA as prognostic factors for OS and RFS of patients with early stage resectable NSCLC [25]. This evidence concerns the gene EGFR and neoplasm.